Diamond Biotech, the first biotech venture capital in China, transferred from IPO to IPO at an underwriting price of 40 yuan per share today (19th). It opened at 45.2 yuan, an increase or decrease of 13%.
Distributing Diamond Biotech’s latest quarter (Q2) financial report, the pre-tax net loss was NT$1.465 billion, the after-tax loss per share was NT$2.31, and the capital after listing was nearly NT$8.5 billion. Chairman Lu Kongming (third from left in the first picture) said: "Everyone knows that Taiwan's biotechnology industry should now be at the level of the electronics industry in the 1980s, that is, in the next 30 years, there is quite a chance of vigorous development. But the army has not moved. Food comes first, and ‘funds’ are the food for the army. This listing will encourage more sustainable venture capital to invest in high-tech emerging industries.”
Diamond Biotechnology goes public
Diamond Biotechnology listing ceremony.
Picture/Lin Zhiyuan Photography
After Diamond Biotechnology goes public: early and late biotechnology innovations must be focused on
Back in 2013, Diamond Biotech was founded by Zhongtian Biotechnology Group, focusing on investing in high-risk biotechnology innovation industries such as new biotech drugs, high-end medical materials, and agricultural biotechnology. Its founding shareholders include Zhongtian Biotech and Fubon Financial. Holdings, Taishin Financial indonesia telegram Holdings, Runtai Group and other companies. So far, Diamond Biotechnology has supported 6 top universities and research institutions in Taiwan to spin out 7 new biotech companies. At the same time, Diamond Biotechnology has donated more than NT$600 million to support the cultivation of high-level talents and medical research, and has supported two biotech companies. The market value of new technology pharmaceutical companies exceeds 30 billion yuan.
Stay on top of the latest AI, semiconductor, and digital trends! Subscribe to the "Digital Times" daily newspaper and social event information
Please enter Email
Different from the general venture capital investment period that has an operating period of 7 to 10 years to facilitate investment recovery, Diamond Biotech is positioned as a "sustainable venture capital company" because they focus on the long technology research and development cycle and high risks of the biotech medical industry. High, it takes a long time to verify.
"I often say that working in this industry is like a cow or a horse. It is very hard to do it without dying, almost day and night, because in addition to complying with regulations and promoting scientific development, we also need to help scientists realize their ideas. ” Lu Kongming pointed out that now that diamond investment can enter the capital market, it will accumulate greater energy and help Taiwan’s new innovation and biotech medical industries grow.
